Outset Medical, Inc. OM

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
44/100
Developing

About Outset Medical, Inc.

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data … Full OM analysis →

Competitive advantage assessment

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.78). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.84). Margin expansion confirms commercial leverage is building.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.24). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.39). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
22

Where OM ranks in Medical Devices

Outset Medical, Inc. ranks #98 of 160 scored companies in Medical Devices by moat score — the top 61%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

Moat scores for companies ranked near OM in Medical Devices
# Company Moat score Rating
94 Nuwellis, Inc. NUWE 44/100 Developing
95 Helius Medical Technologies, In HSDT 44/100 Developing
96 Trinity Biotech plc TRIB 44/100 Developing
97 Nexalin Technology, Inc. NXLIW 44/100 Developing
98 Outset Medical, Inc. OM 44/100 Developing
99 LENSAR, Inc. LNSR 43/100 Developing
100 ClearPoint Neuro Inc. CLPT 43/100 Developing
101 Nexalin Technology, Inc. NXL 43/100 Developing
102 MDAIW MDAIW 42/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How OM scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 22 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 49 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 59 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 60 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 41 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 30 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding OM's moat

What is Outset Medical, Inc.'s moat score?

Outset Medical, Inc. (OM) scores 44 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #98 of 160 scored companies in Medical Devices, the top 61%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Commercial Execution (60/100) and its weakest is Pricing Power & Consumable Moat (22/100).

How does Outset Medical, Inc. compare with other Medical Devices companies?

Outset Medical, Inc. ranks #98 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Nexalin Technology, Inc. (NXLIW) at 44 just above it and LENSAR, Inc. (LNSR) at 43 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Outset Medical, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Outset Medical, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and OM scores: Pricing Power & Consumable Moat (22), R&D Pipeline & Capital Returns (49), FCF Quality & Cash Conversion (59), Commercial Execution (60), Capital Structure & Resilience (41), Growth Durability (30). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000